Nigeria has recorded significant progress in reducing its reliance on foreign-produced medications, with imported drugs now accounting for an estimated 60 to 70 per cent of medicines consumed in the country.
Health sector officials disclosed that the development reflects steady growth in local pharmaceutical manufacturing, driven by policy reforms, increased private sector participation, and renewed government support for indigenous drug producers.
According to industry stakeholders, Nigeria previously depended overwhelmingly on imported medicines, a situation that exposed the country to supply disruptions, foreign exchange pressures, and rising drug costs. However, sustained investment in local production capacity has helped bridge part of the gap, particularly in essential medicines such as antibiotics, analgesics, and basic healthcare products.
Government agencies attributed the improvement to initiatives aimed at strengthening pharmaceutical regulation, encouraging local manufacturing through incentives, and improving access to financing for drug manufacturers. Efforts to align local production with international quality standards were also highlighted as a key factor in expanding confidence in made-in-Nigeria medicines.
Officials noted that while progress has been made, the country still imports a significant volume of specialised and high-end medications. As a result, further investments in technology, research, and skilled manpower are being prioritised to deepen local production and reduce import dependence even further.
Health experts believe that expanding domestic drug manufacturing could enhance national health security, stabilise medicine prices, and create employment opportunities across the pharmaceutical value chain.
The government reaffirmed its commitment to supporting the sector, stating that continued collaboration with investors and regulators would be crucial in achieving long-term self-sufficiency in medicine production.
